Trump says Iran war "close to over" amid hopes for more negotiations
Lineage Cell Therapeutics, Inc. (NYSE American:LCTX) announced Wednesday that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission for the potential offer and sale of its common shares having an aggregate offering price of up to $60 million. The capital raise comes as the stock has surged 240% over the past year to $1.81, giving the company a market capitalization of $450.85 million. The shares may be sold from time to time through or to B. Riley Securities, Inc., under an existing sales agreement dated March 22, 2024.
The prospectus supplement, dated Wednesday, is part of the company’s shelf registration statement on Form S-3 (File No. 333-277758), which was originally filed on March 7, 2024, and declared effective on May 14, 2024. The new supplement updates prior prospectus supplements dated May 14, 2024, and November 12, 2025, and excludes $22,583,663.82 in aggregate gross sales price of common shares previously sold under those supplements and the base prospectus.
According to the filing, the shares offered under the new prospectus supplement (the “ATM Shares”) will be available for sale pursuant to the registration statement, base prospectus, prior supplements, and the current prospectus supplement. The company specified that the report does not constitute an offer to sell or a solicitation of an offer to buy the ATM Shares in any jurisdiction where such an offer or sale would be unlawful.
A legal opinion from Sheppard, Mullin, Richter & Hampton LLP regarding the validity of the shares covered by the prospectus supplement was included as an exhibit to the filing.
This information is based on a press release statement and related SEC filing.
In other recent news, Lineage Cell Therapeutics has reiterated its commitment to advancing its cell therapy initiatives. The company highlighted its achievements for 2025 and shared plans for 2026, focusing on its OpRegen program, which is being developed in collaboration with Roche and Genentech. Notably, data indicates that a single dose of OpRegen can lead to visual improvement lasting at least three years for patients with geographic atrophy secondary to dry age-related macular degeneration. Additionally, H.C. Wainwright has reiterated a Buy rating for Lineage Cell Therapeutics, maintaining a price target of $9.00. The firm pointed out that developments from Roche, a global partner, could be a significant catalyst for the company’s shares. Roche has been expanding sites for the GAlette study, with long-term data showing promising results in reversing geographic atrophy and enhancing visual acuity. These developments underscore the ongoing progress and potential impact of Lineage Cell’s therapies in the biotechnology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.